Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
EMBO Molecular Medicine|January 17, 2012
N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasisWen Liu, Fei Xing, Megumi Iiizumi-Gairani, et al.
Cancer Research|November 25, 2011
Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cellsHiroshi Okuda, Aya Kobayashi, Bo Xia, et al.
Cancers|December 17, 2024
Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck CancerNatsuko Ueda, Masashi Kuroki, Hirofumi Shibata, et al.
Vaccine|December 2, 2022
Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workersHidenori Tanaka, Junji Mukai, Kenichi Kushibiki, et al.
Cancers|April 14, 2026
Clinical Impact of Nivolumab in Sinonasal Mucosal Melanoma: A 14-Year Single-Center Retrospective Study and Comprehensive Literature ReviewKosuke Terazawa, Ryo Utakata, Ryota Iinuma, et al.
Cancer Research|September 17, 2008
RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancerMegumi Iiizumi, Sucharita Bandyopadhyay, Sudha K Pai, et al.
Metabolism: Clinical and Experimental|October 19, 2023
Angiotensin II type 1 receptor-associated protein in immune cells: a possible key factor in the pathogenesis of visceral obesityShunichiro Tsukamoto, Toru Suzuki, Hiromichi Wakui, et al.
The Journal of Biological Chemistry|April 2, 2011
KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFkappaB complex in human prostate cancerWen Liu, Megumi Iiizumi-Gairani, Hiroshi Okuda, et al.
International Journal of Clinical Oncology|May 31, 2019
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)Nobuaki Suzuki, Shoichi Hazama, Takeshi Nagasaka, et al.
Cancer Chemotherapy and Pharmacology|March 22, 2023
A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 studyHiroshi Okuda, Manabu Shimomura, Satoshi Ikeda, et al.
Pageof 13